GlassScriptPhysician profile
Yaser S Bassel
NPI 1376740415
$18,191.39
in general payments reported to CMS, 2019-2025
52 companies · $6,216 in 2025
The $6,216 reported for 2025 was more than what 92% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $674 · 2020: $1,039 · 2021: $1,962 · 2022: $3,235 · 2023: $2,457 · 2024: $2,608 · 2025: $6,216.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,066 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,530 · Consulting Fee: $1,420 · Honoraria: $258 · Education: $8.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,065.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,530.00 |
| Consulting Fee | $1,420.00 |
| Honoraria | $257.63 |
| Education | $8.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axonics, INC. | $4,378.54 | 2020-2024 | Axonics, Bulkamid |
| Medtronic, INC. | $2,630.12 | 2021-2025 | Nuro, Interstim |
| Ferring Pharmaceuticals INC. | $1,849.74 | 2019-2025 | Adstiladrin |
| Pfizer INC. | $1,318.21 | 2019-2025 | |
| Abbvie INC. | $790.92 | 2019-2025 | Botox, Lupron Depot |
| Teleflex LLC | $785.61 | 2021-2025 | Barrigel, Urolift |
| Astellas Pharma US INC | $623.18 | 2019-2024 | Xtandi |
| Procept Biorobotics Corporation | $565.98 | 2020-2025 | Aquabeam System |
| Boston Scientific Corporation | $465.21 | 2019-2025 | Axonics, Spaceoar Vue System - 10ml |
| Endo Pharmaceuticals INC. | $397.76 | 2020-2024 | Xiaflex, Aveed, Edex |
| Bayer Healthcare Pharmaceuticals INC. | $396.99 | 2022-2025 | |
| Coloplast Corp | $335.60 | 2019-2024 | Speedicath |
| Dendreon Pharmaceuticals LLC | $319.90 | 2019-2025 | Provenge |
| Janssen Biotech, INC. | $303.01 | 2019-2025 | Erleada |
| Tolmar Pharmaceuticals, INC. | $236.96 | 2019-2022 |
Show all 50 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,817.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yaser Bassel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.